Previous research has demonstrated that CCR2, by binding to its ligand CCL2, drives the migration of CD14+ CD16+ monocytes from the peripheral blood to tumor sites, constituting a key pathway for immune cell recruitment to the TME[61]. This evidence concerns the gene CCR2 and neoplasm.